Abstract | BACKGROUND: Self-expanding metal stents (SEMS) are increasingly used in the treatment of malignant large bowel obstruction in the setting of inoperable colorectal cancer. Perforation is a well-known complication associated with these devices. The addition of the vascular endothelial growth factor inhibitor bevacizumab is suspected to increase the rate, but the extent of the increase is not known. METHODS: We retrospectively reviewed the records of patients receiving SEMS in tertiary hospitals in Calgary, Alta., between October 2001 and January 2012. RESULTS: CONCLUSION: Our case series and other studies suggest that bevacizumab may increase the risk of colonic perforation in the setting of SEMS. Caution should be used when combining these therapies.
|
Authors | Amal Imbulgoda, Anthony MacLean, John Heine, Sebastien Drolet, Michael M Vickers |
Journal | Canadian journal of surgery. Journal canadien de chirurgie
(Can J Surg)
Vol. 58
Issue 3
Pg. 167-71
(Jun 2015)
ISSN: 1488-2310 [Electronic] Canada |
PMID | 25799132
(Publication Type: Evaluation Study, Journal Article, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Bevacizumab
|
Topics |
- Adenocarcinoma
(complications, drug therapy)
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- Bevacizumab
- Colonic Diseases
(etiology, therapy)
- Colorectal Neoplasms
(complications, drug therapy)
- Combined Modality Therapy
- Female
- Humans
- Intestinal Obstruction
(etiology, therapy)
- Intestinal Perforation
(etiology)
- Male
- Middle Aged
- Palliative Care
(methods)
- Retrospective Studies
- Stents
(adverse effects)
- Treatment Outcome
|